Article Correctness Is Author's Responsibility: Triggering tumor antiviral immune response in triple negative ****** cancer

(Baylor College of Medicine) Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body's immune response.